GlassScriptPhysician profile
Jami Kaye Kamp
NPI 1801152095
$1,509.58
in general payments reported to CMS, 2019-2025
19 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.58 · 2022: $332 · 2023: $383 · 2024: $494 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $411.65 | 2022-2025 | |
| Pfizer INC. | $221.94 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.76 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $82.18 | 2022-2024 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $80.83 | 2022-2025 | Camzyos |
| Edwards Lifesciences Corporation | $72.71 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.80 | 2022-2023 | Jardiance |
| Amgen INC. | $66.10 | 2022-2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $59.39 | 2023-2024 | Inpefa |
| Abbott Laboratories | $52.16 | 2022-2024 | Cardiomems |
| Merck Sharp & Dohme LLC | $43.15 | 2023 | Verquvo |
| Scpharmaceuticals INC. | $32.44 | 2024 | |
| Vyne Pharmaceuticals INC. | $26.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.18 | 2022 | |
| Daiichi Sankyo INC. | $20.90 | 2024 | Injectafer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.59 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.60 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $14.39 | 2022 | |
| Esperion Therapeutics, INC. | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Kamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.